Biostatistics and programming services
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
20
NCT03216538
Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 8, 2018
Completion: Jul 1, 2020
Loading map...